Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00847483 · ClinicalTrials.gov registry record · Phase 4
Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US
A Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 375
- Enrollment target
NCT00847483: Completed Phase 4 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
NCT00847483 is a Phase 4 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 375 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00847483, a Phase 4 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 375 participants
- Enrollment target
Study Summary
Compare the IOP lowering properties of latanoprost, travoprost and bimatoprost
Interventions
- DRUG latanoprost 0.005% ophthalmic solution
- DRUG Travoprost 004% sterile ophthalmic solution
- DRUG Bimatoprost .03% sterile ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2002-01 |
| Est. Completion | 2002-08 |
| Phase | Phase 4 |
What the finished NCT00847483 record still lists
NCT00847483 is an interventional study that assigns participants to a tested intervention. The registered 375 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 3 interventions - of which latanoprost 0.005% ophthalmic solution is the first listed.
NCT00847483 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00847483 about?
NCT00847483 is a clinical study titled "Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US". Compare the IOP lowering properties of latanoprost, travoprost and bimatoprost
What is the current status of trial NCT00847483?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 375 participants. The study started on 2002-01. Estimated completion is 2002-08.
What interventions are being tested in trial NCT00847483?
The interventions under investigation include: latanoprost 0.005% ophthalmic solution (DRUG), Travoprost 004% sterile ophthalmic solution (DRUG), Bimatoprost .03% sterile ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT00847483?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00847483's enrollment target sits among peer trials
375 223rd of 2000 higher than 1,778 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia